What is Beyfortus (nirsevimab‑alip), and how should it be dosed and administered for NICU infants, including its indications, contraindications, and supplemental dosing?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Beyfortus (Nirsevimab) for NICU Families

All NICU infants should receive a single dose of Beyfortus before discharge or shortly after, with dosing based solely on weight: 50 mg for infants under 5 kg and 100 mg for infants 5 kg or greater. 1

What is Beyfortus?

Beyfortus (nirsevimab) is a long-acting monoclonal antibody that provides passive immunity against respiratory syncytial virus (RSV), the leading cause of hospitalization in U.S. infants. Unlike palivizumab which requires monthly injections, Beyfortus provides protection for an entire RSV season with just one dose. 1

RSV causes approximately 50,000-80,000 hospitalizations and 100-300 deaths annually among U.S. infants and children under 5 years. Premature infants face three times the hospitalization risk compared to term infants. 1

Who Should Receive Beyfortus in the NICU?

First RSV Season (All NICU Infants):

  • All infants under 8 months of age born during or entering their first RSV season
  • This includes:
    • Premature infants (any gestational age)
    • Term infants
    • Infants with chronic lung disease of prematurity
    • Infants with congenital heart disease
    • Healthy infants without underlying conditions 1, 2

Second RSV Season (High-Risk Only):

  • Children 8-19 months who remain vulnerable to severe RSV disease entering their second season
  • Dose: 200 mg (given as two 100 mg injections at different sites)
  • This applies to the same high-risk children who would have qualified for palivizumab 1

Dosing for NICU Infants

Weight-based dosing (use actual body weight, not corrected):

  • Under 5 kg (under 11 lbs): 50 mg single intramuscular injection
  • 5 kg or greater (11 lbs or more): 100 mg single intramuscular injection 1, 2

Critical point: Use chronologic age, not corrected gestational age, to determine eligibility. 1

Timing of Administration

For NICU infants born during RSV season (October-March):

  • Administer within 1 week of birth
  • Can be given during birth hospitalization or outpatient setting
  • Infants with prolonged NICU stays should receive Beyfortus shortly before or promptly after discharge 1

For infants born outside RSV season:

  • Administer shortly before RSV season begins (typically late September/October)
  • Can give at any time during the season if not yet received 1

Important caveat: Beyfortus is NOT recommended for prevention of hospital-acquired RSV infection—there is no evidence supporting this use. 1

Administration Details

Route: Intramuscular injection, preferably in the anterolateral thigh (avoid gluteal muscle due to sciatic nerve risk) 2

Co-administration with vaccines:

  • Can be given simultaneously with routine childhood vaccines
  • Use separate syringes at different injection sites
  • Does not interfere with vaccine immune response 1

Interaction with palivizumab:

  • Do NOT give palivizumab to infants who already received Beyfortus in the same season
  • Infants who received palivizumab in their first season CAN receive Beyfortus in their second season if they remain high-risk 2

Contraindications

Absolute contraindication: History of serious hypersensitivity reactions (including anaphylaxis) to nirsevimab or any excipients 2

Use with caution in:

  • Infants with thrombocytopenia
  • Any coagulation disorder
  • Infants on anticoagulation therapy 2

Safety Profile

The safety data from over 3,200 infants shows:

  • Most common adverse reactions: rash (0.9%) and injection site reactions (0.3%)
  • No treatment-related anaphylaxis or thrombocytopenia
  • Deaths (<1%) were all unrelated to treatment
  • Similar safety profile whether given to healthy infants or those with chronic lung disease/congenital heart disease 3

Real-world data from 1,462 newborns showed no adverse events following immunization, with high coverage rates (94%) and reassuring short-term safety. 4

Efficacy

Proven protection:

  • 79.5% reduction in medically attended RSV lower respiratory tract infections
  • 77.3% reduction in RSV hospitalizations
  • 86% reduction in very severe RSV requiring oxygen or IV fluids
  • Additional benefits: 43.8% reduction in any-cause respiratory hospitalizations and 23.6% reduction in antibiotic prescriptions 5

Real-world effectiveness shows even more dramatic results, with 96.5% reduction in RSV-confirmed infections and 67.3% decrease in emergency department visits for respiratory infections. 6

Key Pitfalls to Avoid

  1. Don't delay administration in premature infants—they need protection before discharge, not after
  2. Don't use corrected age—use chronologic age for eligibility determination
  3. Don't give during NICU stay to prevent nosocomial RSV—no evidence supports this
  4. Don't substitute palivizumab once Beyfortus is given in the same season
  5. Don't skip high-risk infants thinking they'll get palivizumab—Beyfortus replaces palivizumab for eligible infants 1

Geographic Considerations

Most continental U.S. locations: October through March administration

Special populations requiring local guidance:

  • Southern Florida, Hawaii, Puerto Rico, U.S. Virgin Islands, Guam, Pacific Islands (unpredictable seasonality)
  • Alaska (longer, less predictable RSV season) 1

References

Related Questions

Can a 3‑week‑old infant receive Beyfortus (nirsevimab)?
What is the efficacy of the RSV monoclonal antibody nirsevimab in preventing medically‑attended lower respiratory tract infection and hospitalization in infants?
What RSV prophylaxis should be given to a newborn infant before hospital discharge, including appropriate dosing and timing?
What are the updated 2025 guidelines for respiratory syncytial virus (RSV) vaccination and monoclonal antibody use compared to the 2024 recommendations?
What are the risks of administering Beyfortus (nirsevimab) to adults?
What is the maximum dose of cefepime for a patient on hemodialysis?
What is the appropriate management of hypercapnic respiratory failure?
What is the most appropriate laxative for a patient with Parkinson’s disease who has not had a bowel movement for one week?
What antibiotic is recommended in guidelines for preoperative prophylaxis and what is the appropriate dose?
Can a patient with hepatopathy and markedly elevated liver enzymes (AST ≈2.5 ukat/L, ALT ≈3.9 ukat/L, LDH ≈4.65 µkat/L) be treated with atorvastatin 80 mg?
What is the appropriate urgent management for a neonate presenting with gangrene?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.